New vaccine principle delivers stronger and faster immune response
Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL). PROPEL (Pralatrexate in patients with Relapsed Or refractory PEripheral T-cell Lymphoma) findings were presented by
Full Post: Pralatrexate shows promise for T-Cell lymphoma
A new vaccine principle is being developed by scientists at the University of Copenhagen which - if it works to its full expected potential - could help to save millions of lives and revolutionise current vaccine technology.
The ‘InVacc’ platform, as it is known, represents an advance on the original DNA vaccines and generates new vaccines with greatly enhanced properties. The platform consists of a chain of amino acids attached to a gene of the virus being vaccinated against. This genetic cocktail is then inserted into an incapacitated flu-like virus such as the adenovirus and injected into the body, where it triggers a broader and more aggressive immune response, enabling the immune system to quickly seek out and destroy the disease when it invades.
“We are excited to be working on the vaccine technology”, says Associate Professor Jan Pravsgaard, the lead scientist behind the project. “The platform has proved very effective in our recent tests and could have enormous potential. In principle, vaccines of this type could be used to inoculate against a range of deadly viruses, bacteria and other disease-causing agents and even be used to cure certain cancers once they take hold.”
Tests of the vaccine platform on mice so far look extremely promising with the scientists able to provide 100% protection against different, lethal strains of flu given to the test animals.
The scientists also believe that the new technology will be effective despite the ability of different viruses and bacteria to constantly mutate and develop resistance.
Key benefits of the new technology:
- The new platform delivers a broad and very powerful immune re-sponse, enabling the immune system to defeat invading pathogens.
- Unlike many vaccines, InVacc activates the CD4+ T cells of the immune system, which govern and coordinate the other immune system attack cells. For reasons not yet fully understood, activating the CD4+ cells enhances the response of the associated attack cells (producing large numbers of CD8+ cells) and is an important reason why the platform is able to deliver such a strong immune response.
- InVacc provides rapid protection. In animal tests, complete protection was achieved in less than 3 days after a single vaccination. This could have significant implications for the handling of epidemics, quickly halting infection rates and preventing major outbreaks.
The Scandinavian company Novo A/S and the Novo Nordisk Foundation have such faith in the new technology that they have already invested funds to create a strategic plan for development and use of the platform. “The grants awarded through our Novo Seeds programme are only for very select projects that show outstanding promise, both scientifically and commercially, explains Novo Seeds Investment Director, Stephen Christgau.” “The InVacc platform is definitely one of those. Our grants will help the team to develop and commercialise their groundbreaking research and validate the advantages of the vaccine platform against competing technologies”.
Peter Holst, PhD, from the research team, (together with the Technical Transfer Unit at the University of Copenhagen), are currently also seeking backing from international funds to take the project to its next phase of development and ultimately into clinical trials.
Vical Incorporated has announced that the company’s Vaxfectin-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial. The company previously reported that the vaccines had achieved potentially protective levels of antibody responses in
Full Post: Vaxfectin-formulated H5N1 pandemic influenza achieves T-cell responses and cross-clade reactivity in humans
New industry-supported research from Finland suggests that Cervarix, an HPV vaccine given to girls in Europe and elsewhere, is safe for boys as well. “The results show that the vaccine does generate an immune response and is generally well-tolerated,” said study co-author Gary Dubin, M.D., of vaccine maker GlaxoSmithKline. It is not clear, however, whether
Full Post: Immunogenicity and safety of human papillomavirus vaccine in healthy boys
The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp. The Court’s ruling is final and can not be appealed. The challenge was made against elements of a patent filed, and subsequently published in 1994, by Dr. Yvonne
Full Post: Advaxis wins European patent case involving Lovaxin-C vaccine
Research led by Johns Hopkins Children’s Center scientists has figured out why a respiratory syncytial virus vaccine used in 1966 to inoculate children against the infection instead caused severe respiratory disease and effectively stopped efforts to make a better one. The findings, published online on Dec. 14 in Nature Medicine, could restart work on
Full Post: Researchers solve failed vaccine mystery
A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy. Botulism is caused by a bacterium, Clostridium botulinum, which produces toxins that cause paralysis and often death, as the muscles that control breathing fail. Out
Full Post: New nasal spray vaccine shown to be effective against botulism